Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral COVID-19 vaccine (triple antigen)
- Development stage
- Unknown
- Lead developer
- Oramed Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The oral COVID-19 vaccine (triple antigen) is a virus-like particle (VLP) vaccine candidate developed by Oravax Medical, a joint venture between Oramed Pharmaceuticals and Premas Biotech. Unlike most COVID-19 vaccines that target only the Spike (S) protein, this candidate targets three SARS-CoV-2 surface proteins: the Spike, Membrane (M), and Envelope (E) proteins. This triple-antigen approach is intended to provide broader protection and increase resilience against viral mutations by targeting regions described as less susceptible to mutation. The vaccine utilizes Oramed's Protein Oral Delivery (POD) technology, which protects the protein cargo from degradation in the gastrointestinal tract and facilitates absorption, and Premas's D-Crypt platform for VLP production. It is designed for oral administration via capsule, potentially improving accessibility and ease of distribution compared to injectable vaccines.
- Other names
- Triple Antigen oral COVID-19 vaccineOravax oral COVID-19 vaccineOravax VLP vaccine
02
Targets
SARS-CoV-2 spikeE (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on oral COVID-19 vaccine (triple antigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral COVID-19 vaccine (triple antigen).